Industry Update
Industry Update
Who is left to bring gene
therapy to market?
With the withdrawal of most large
companies from gene therapy and
the worsening financial climate, only
a handful of publicly quoted firms
are now in a position to bring
clinical products to market in the
next few years. In order to do this,
they will need both deep pockets of
cash and strong corporate partners.
In Europe, the recent trouble at
Transgene, the refocusing of Cru-
Cell (previously IntroGene)